The 2011 Reaxys(R) PhD Prize for Chemistry Research Opens for Entries

NEUCHATEL, Switzerland, February 2, 2011 - Elsevier Properties SA announces the launch of the 2011 Reaxys PhD Prize,
a global competition for candidates currently studying for a PhD or having
completed a PhD within the last 12 months.

The prize will be awarded for original and innovative research in
organic, organometallic and inorganic chemistry to the candidates that
demonstrate excellence in methodology and approach in a peer-reviewed
publication. Three prize winners will each receive a check for $2000 and be
invited to present their research at the Winners' Symposium, to be held
during the 14th Asian Chemical Congress, 5 - 8 September, 2011 in Bangkok,
Thailand.

David Evans PhD, Scientific Affairs Director at Elsevier Properties SA
said, "The Reaxys PhD Prize celebrates innovation and creativity in chemistry
research from around the world, values which lie at the heart Reaxys itself."
He continued, "In 2010 we received over 300 submissions from around the world
covering the breadth of modern chemistry including representatives from most
of the leading chemistry universities. The quality of research was
outstanding, and the finalists and winners are clearly at the cutting edge of
chemistry research. A high bar has been set for 2011."

All entries will be evaluated by a review board of leading international
chemists, chaired by the following members of the Reaxys Advisory Board:

    - Professor A. G. M. Barrett - Imperial College London, UK
    - Professor B. M. Trost - Stanford University, USA
    - Professor H. N. C. Wong - Chinese University of Hong Kong, China

Submissions will be reviewed based upon originality, innovation,
importance to the field, applicability, rigor of approach and publication
quality.

All submissions must include a PhD Supervisor letter of recommendation, a
CV and a representative peer-reviewed piece of published research. Entries
should be submitted by February 28, 2011 at the Reaxys PhD Prize website:
prize.reaxys.com

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed Elsevier for
the management of intellectual property. Elsevier Properties SA owns the
PharmaPendium, Beilstein and Reaxys databases. Trademarks including
Reaxys(R), PharmaPendium(TM) and The Lancet(R) are owned and protected by
Elsevier Properties SA and used under license. For additional information see
www.reedelsevier.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com/) and Cell
(www.cell.com/), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (www.sciencedirect.com/), SciVerse Scopus
(www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD
Consult (www.mdconsult.com/) and Nursing Consult (
www.nursingconsult.com/), which enhance the productivity of science
and health professionals, and the SciVal suite (www.scival.com/) and
MEDai's Pinpoint Review (www.medai.com/), which help research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com/) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com/), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact
    Harald Boersma
    +31-20-485-27-36
    h.boersma@elsevier.com

Media Contact: Harald Boersma, +31-20-485-27-36, h.boersma at elsevier.com